Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

Chanhee Han; Stefania Bellone; Peter E. Schwartz; Serengulam V. Govindan; Robert M. Sharkey; David M. Goldenberg; Alessandro D. Santin

Gynecologic Oncology Reports (Aug 2018)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

Chanhee Han,
Stefania Bellone,
Peter E. Schwartz,
Serengulam V. Govindan,
Robert M. Sharkey,
David M. Goldenberg,
Alessandro D. Santin

Affiliations

Chanhee Han: Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States
Stefania Bellone: Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States
Peter E. Schwartz: Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States
Serengulam V. Govindan: Immunomedics, Inc., 300 The American Road, Morris Plains, NJ 07950, United States
Robert M. Sharkey: Immunomedics, Inc., 300 The American Road, Morris Plains, NJ 07950, United States
David M. Goldenberg: Immunomedics, Inc., 300 The American Road, Morris Plains, NJ 07950, United States
Alessandro D. Santin: Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States; Corresponding author at: 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT 06520, USA.

Journal volume & issue: Vol. 25
pp. 37 – 40

Abstract

Read online

Background: Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited. Case: We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experienced a dramatic response to sacituzumab govitecan, a novel antibody-drug conjugate (ADC) targeting human trophoblast-cell-surface antigen (TROP-2), after failing multiple chemotherapy and immunotherapy. The impressive clinical response (66% reduction of target lesions by RECIST 1.1 with a duration response of over 10 months) was confirmed with serial CT scans in the absence of significant adverse events. Conclusion: Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted. Keywords: Sacituzumab govitecan, IMMU-132, Uterine serous carcinoma, Recurrent, Treatment-resistant

Published in Gynecologic Oncology Reports

ISSN: 2352-5789 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Gynecology and obstetrics; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/gynecologic-oncology-reports/

About the journal